Tags

Type your tag names separated by a space and hit enter

Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors.
Cancer Manag Res. 2020; 12:4585-4593.CM

Abstract

Purpose

Immune checkpoint inhibitors (ICIs) have been approved for various types of cancer; however, they cause a broad spectrum of immune-related adverse events (irAEs). The association between the development of irAEs and the clinical benefit remains uncertain. We aimed to evaluate the association of irAEs and the treatment efficacy in real-world practice.

Patients and Methods

We conducted a retrospective study on patients with recurrent or metastatic non-small-cell lung cancer, malignant melanoma, renal cell carcinoma, or gastric cancer who received anti-PD-1/PD-L1 antibodies (nivolumab, pembrolizumab, or atezolizumab) at the Keio University Hospital between September 2014 and January 2019. We recorded treatment-related AEs from medical records and graded them using the Common Terminology Criteria for Adverse Events version 4. We performed an overall survival (OS) analysis using a Cox proportional hazards model and the shared frailty model.

Results

Of 212 patients eligible for this study, 108 experienced irAEs and 42 developed multiple irAEs. The median OS was significantly longer in the irAEs than in the no-irAE group (28.1 months vs 12.7 months; hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.33-0.73; P = 0.0004). Moreover, the OS of patients with multiple irAEs was significantly longer than that of patients with a single irAE (42.3 months vs 18.8 months; HR, 0.473; 95% CI, 0.346-0.647; P < 0.0001).

Conclusion

Our single-center retrospective study revealed a significant tendency associating the development of multiple irAEs with favorable prognoses.

Authors+Show Affiliations

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.Department of Pharmacy, Keio University Hospital, Tokyo, Japan.Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.Department of Neurology, Keio University School of Medicine, Tokyo, Japan.Department of Urology, Keio University School of Medicine, Tokyo, Japan.Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32606951

Citation

Shimozaki, Keitaro, et al. "Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data On Various Solid Tumors." Cancer Management and Research, vol. 12, 2020, pp. 4585-4593.
Shimozaki K, Sukawa Y, Beppu N, et al. Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors. Cancer Manag Res. 2020;12:4585-4593.
Shimozaki, K., Sukawa, Y., Beppu, N., Kurihara, I., Suzuki, S., Mizuno, R., Funakoshi, T., Ikemura, S., Tsugaru, K., Togasaki, K., Kawasaki, K., Hirata, K., Hayashi, H., Hamamoto, Y., Takaishi, H., & Kanai, T. (2020). Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors. Cancer Management and Research, 12, 4585-4593. https://doi.org/10.2147/CMAR.S247554
Shimozaki K, et al. Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data On Various Solid Tumors. Cancer Manag Res. 2020;12:4585-4593. PubMed PMID: 32606951.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors. AU - Shimozaki,Keitaro, AU - Sukawa,Yasutaka, AU - Beppu,Noriko, AU - Kurihara,Isao, AU - Suzuki,Shigeaki, AU - Mizuno,Ryuichi, AU - Funakoshi,Takeru, AU - Ikemura,Shinnosuke, AU - Tsugaru,Kai, AU - Togasaki,Kazuhiro, AU - Kawasaki,Kenta, AU - Hirata,Kenro, AU - Hayashi,Hideyuki, AU - Hamamoto,Yasuo, AU - Takaishi,Hiromasa, AU - Kanai,Takanori, Y1 - 2020/06/16/ PY - 2020/01/29/received PY - 2020/05/13/accepted PY - 2020/7/2/entrez PY - 2020/7/2/pubmed PY - 2020/7/2/medline KW - immune checkpoint inhibitors KW - prognosis KW - programmed cell death 1 SP - 4585 EP - 4593 JF - Cancer management and research JO - Cancer Manag Res VL - 12 N2 - Purpose: Immune checkpoint inhibitors (ICIs) have been approved for various types of cancer; however, they cause a broad spectrum of immune-related adverse events (irAEs). The association between the development of irAEs and the clinical benefit remains uncertain. We aimed to evaluate the association of irAEs and the treatment efficacy in real-world practice. Patients and Methods: We conducted a retrospective study on patients with recurrent or metastatic non-small-cell lung cancer, malignant melanoma, renal cell carcinoma, or gastric cancer who received anti-PD-1/PD-L1 antibodies (nivolumab, pembrolizumab, or atezolizumab) at the Keio University Hospital between September 2014 and January 2019. We recorded treatment-related AEs from medical records and graded them using the Common Terminology Criteria for Adverse Events version 4. We performed an overall survival (OS) analysis using a Cox proportional hazards model and the shared frailty model. Results: Of 212 patients eligible for this study, 108 experienced irAEs and 42 developed multiple irAEs. The median OS was significantly longer in the irAEs than in the no-irAE group (28.1 months vs 12.7 months; hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.33-0.73; P = 0.0004). Moreover, the OS of patients with multiple irAEs was significantly longer than that of patients with a single irAE (42.3 months vs 18.8 months; HR, 0.473; 95% CI, 0.346-0.647; P < 0.0001). Conclusion: Our single-center retrospective study revealed a significant tendency associating the development of multiple irAEs with favorable prognoses. SN - 1179-1322 UR - https://www.unboundmedicine.com/medline/citation/32606951/Multiple_Immune-Related_Adverse_Events_and_Anti-Tumor_Efficacy:_Real-World_Data_on_Various_Solid_Tumors L2 - https://dx.doi.org/10.2147/CMAR.S247554 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.